OverviewSuggest Edit

Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

TypePublic
Founded2014
HQCambridge, MA, US
Websiteintelliatx.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2020)270(+28%)
Revenue (FY, 2019)$43.1 M(+42%)
Share Price (Jan 2021)$81.9 (-1%)
Cybersecurity ratingBMore

Key People/Management at Intellia Therapeutics

John Leonard

John Leonard

President, Chief Executive Officer & Director
Eliana Clark

Eliana Clark

Senior Vice President, Technical Operations
Glenn Goddard

Glenn Goddard

Executive Vice President, Chief Financial Officer
José Rivera

José Rivera

Executive Vice President, General Counsel and Corporate Secretary
David Lebwohl

David Lebwohl

Executive Vice President, Chief Medical Officer
Fred Cohen

Fred Cohen

Independent Director
Show more

Intellia Therapeutics Office Locations

Intellia Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
40 Erie St #130
Show all (1)

Intellia Therapeutics Financials and Metrics

Intellia Therapeutics Revenue

Intellia Therapeutics's revenue was reported to be $43.10 m in FY, 2019
USD

Revenue (Q3, 2020)

22.2m

Net income (Q3, 2020)

(27.8m)

EBIT (Q3, 2020)

(28.1m)

Market capitalization (15-Jan-2021)

5.3b

Closing stock price (15-Jan-2021)

81.9

Cash (30-Sept-2020)

179.7m

EV

5.1b
Intellia Therapeutics's current market capitalization is $5.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

30.4m43.1m

Cost of goods sold

Gross profit

30.4m43.1m

Gross profit Margin, %

100%100%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

7.7m7.4m10.4m11.1m10.6m12.9m16.3m22.2m

Cost of goods sold

Gross profit

10.4m

Gross profit Margin, %

100%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

273.1m340.7m58.9m57.2m

Accounts Receivable

6.5m10.5m7.5m4.6m

Prepaid Expenses

3.7m3.4m5.1m

Inventories

1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.6b)(67.5m)(85.3m)(99.5m)

Depreciation and Amortization

3.0k3.0m4.5m

Inventories

(285.0k)

Accounts Payable

163.0k(488.0k)232.0k1.9m
USDQ1, 2016

Financial Leverage

-2.8 x
Show all financial metrics

Intellia Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Intellia Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Intellia Therapeutics Online and Social Media Presence

Embed Graph

Intellia Therapeutics News and Updates

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today outlined its expected 2021 milestones and the following strategic…

Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy

Thinking about trading options or stock in Rambus, Intellia Therapeutics, BioCryst Pharmaceuticals, Arcturus Therapeutics, or FuelCell Energy?

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RMBS, NTLA, BCRX, ARCT, and FCEL. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company’s wholly owned Wilms’ Tumor 1 (WT1)-directed T cell receptor (TCR)-T cell therapy candidate for the treatment of acute myeloid leuk…

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its third quarter 2020 financial results and operational h…
Show more

Intellia Therapeutics Blogs

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the closing of an underwritten public offering of

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Funding from the Bill and Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients CAMBRIDGE, Mass. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill and Melinda

Intellia Therapeutics Announces Third Quarter 2020 Financial Results

Intellia Therapeutics Announces Third Quarter 2020 Financial Results Content Import Thu, 11/05/2020 - 07:30 Intellia Therapeutics Announces Third Quarter 2020 Financial Results Nov 5, 2020 This release is a backfill from a News Wire …

Wells Fargo: Yanan Zhu

Wells Fargo: Yanan Zhu John.Bissaillo… Wed, 10/14/2020 - 08:09 Yanan Zhu Wells Fargo Yanan.Zhu@wellsfargo.com

John F. Crowley

John F. Crowley John.Bissaillo… Sun, 10/11/2020 - 20:56 John F. Crowley Director John F. Crowley is a visionary advocate and leader in advancing therapies for people living with rare diseases. Currently, he is the chairman and CEO of Amicus Therapeutics, a global…

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology Content Import Wed, 10/07/2020 - 16:21 Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning…
Show more

Intellia Therapeutics Frequently Asked Questions

  • When was Intellia Therapeutics founded?

    Intellia Therapeutics was founded in 2014.

  • Who are Intellia Therapeutics key executives?

    Intellia Therapeutics's key executives are John Leonard, Eliana Clark and Glenn Goddard.

  • How many employees does Intellia Therapeutics have?

    Intellia Therapeutics has 270 employees.

  • What is Intellia Therapeutics revenue?

    Latest Intellia Therapeutics annual revenue is $43.1 m.

  • What is Intellia Therapeutics revenue per employee?

    Latest Intellia Therapeutics revenue per employee is $159.6 k.

  • Who are Intellia Therapeutics competitors?

    Competitors of Intellia Therapeutics include 4D Molecular Therapeutics, LogicBio Therapeutics and Sarepta Therapeutics.

  • Where is Intellia Therapeutics headquarters?

    Intellia Therapeutics headquarters is located at 40 Erie St #130, Cambridge.

  • Where are Intellia Therapeutics offices?

    Intellia Therapeutics has an office in Cambridge.

  • How many offices does Intellia Therapeutics have?

    Intellia Therapeutics has 1 office.